IDH1 and astrocytoma (excluding glioblastoma): Together with our previous studies in low-grade gliomas, we conclude that PROX1 is a pathway-specific biomarker for IDH-mutant, 1p19q non-codeleted astrocytomas that may be used to identify high-risk patients.